Associated Papers
Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.
He C et al.
Journal of Cancer Research and Clinical Oncology, 2022
EGFR Gene Mutation and Methodological Evaluation in 399 Patients with Non-small Cell Lung Cancer.
Zheng HY et al.
Current Medical Science, 2020
Discrepancies between ALK protein disruption and occurrence of ALK gene rearrangement in Polish NSCLC patients.
Grenda A et al.
Journal of Thoracic Disease, 2018
Analytic and Clinical Validation of an Ultrasensitive, Quantitative Polymerase Chain Reaction Assay for EGFR Mutation Analysis With Circulating Tumor DNA.
Wang X et al.
Archives of Pathology & Laboratory Medicine, 2017
Characterization of common and rare mutations in EGFR and associated clinicopathological features in a large population of Chinese patients with lung cancer.
Wei B et al.
Pathology, Research and Practice, 2017
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations.
Krawczyk P et al.
Oncology Letters, 2017
High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR.
Wang F et al.
Journal of Translational Medicine, 2013
23557218 (PubMed )
Supplement: 1479-5876-11-90-S1.xls › Sheet1
Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology.
Roma C et al.
Biomed Research International, 2013
Select a paper to view details